Eton Pharmaceuticals (ETON) investor relations material

Executive summary

• Q1 2026 product sales reached $24.3 million, up 73% year-over-year, driven by strong growth across the rare disease portfolio and new product launches, including INCRELEX, GALZIN, ALKINDI SPRINKLE, Carglumic Acid, and KHINDIVI.

• Launched DESMODA and HEMANGEOL, expanding into pediatric dermatology and endocrinology, with enhanced patient support and streamlined distribution.

• Raised full-year 2026 revenue guidance to exceed $120 million, reflecting robust Q1 performance and positive trends into Q2.

• Adjusted EBITDA for Q1 was $5.7 million (24% of revenue), with expectations to surpass 30% margin for the full year.

• Net income for Q1 2026 was $1.6 million, reversing a $1.6 million loss in Q1 2025.

Financial highlights

• Q1 2026 revenue increased 40% to $24.3 million from $17.3 million in Q1 2025; product and royalty revenue rose 73%.

• Gross profit was $14.7 million, up 49% year-over-year; adjusted gross profit was $16.2 million (67% of revenue).

• Adjusted EBITDA margin improved to 24% from 21% year-over-year.

• Generated $7.4 million in operating cash flow; ended Q1 with $19.7 million in cash after $14 million HEMANGEOL payment.

• Operating expenses increased to $12.3 million in Q1 2026, mainly due to higher R&D and G&A costs.

Outlook and guidance

• Full-year 2026 revenue expected to exceed $120 million, with adjusted EBITDA margin above 30%.

• Targeting 50% adjusted EBITDA margin by 2028 and $200 million annual revenue run rate by end of 2027.

• HEMANGEOL expected to become the largest product by 2027; DESMODA peak sales projected at $30–$50 million.

• Ongoing investments in late-stage development candidates and label expansions are anticipated to drive long-term growth.